The A to I editing landscape in melanoma and its relation to clinical outcome

References

• Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013;19(2):209–216.
   PubMed Web of Science ®Google Scholar
• Han L, Diao L, Yu S, et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell. 2015;28(4):515–528.
   PubMed Web of Science ®Google Scholar
• Paz-Yaacov N, Bazak L, Buchumenski I, et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 2015;13(2):267–276.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang C-S, Varelas X, et al. Altered RNA editing in 3’ UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci Rep. 2016;6(1):23226.
   PubMedGoogle Scholar
• Zinshteyn B, Nishikura K. Adenosine-to-inosine RNA editing. Wiley Interdiscip Rev Syst Biol Med. 2009;1(2):202–209.
   PubMed Web of Science ®Google Scholar
• Baysal BE, Sharma S, Hashemikhabir S, et al. RNA editing in pathogenesis of cancer. Cancer Res. 2017;77(14):3733–3739.
   PubMed Web of Science ®Google Scholar
• Blanc V, Davidson NO. C-to-U RNA editing: mechanisms leading to genetic diversity. J Biol Chem. 2003;278(3):1395–1398.
   PubMed Web of Science ®Google Scholar
• Smith HC, Bennett RP, Kizilyer A, et al. Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol. 2012;23(3):258–268.
   PubMed Web of Science ®Google Scholar
• Kim U, Wang Y, Sanford T, et al. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A. 1994;91(24):11457–11461.
   PubMed Web of Science ®Google Scholar
• Melcher T, Maas S, Herb A, et al. A mammalian RNA editing enzyme. Nature. 1996;379(6564):460–464.
   PubMed Web of Science ®Google Scholar
• Chen CX, Cho DS, Wang Q, et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA. 2000;6(5):755–767.
   PubMed Web of Science ®Google Scholar
• Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995;15(10):5376–5388.
   PubMed Web of Science ®Google Scholar
• Gerber AP, Keller W. RNA editing by base deamination: more enzymes, more targets, new mysteries. Trends Biochem Sci. 2001;26(6):376–384.
   PubMed Web of Science ®Google Scholar
• Wang Q, Khillan J, Gadue P, et al. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science. 2000;290(5497):1765–1768.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Maas S, Single FN, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78–81.
   PubMed Web of Science ®Google Scholar
• Wahlstedt H, Daniel C, Ensterö M, et al. Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009;19(6):978–986.
   PubMed Web of Science ®Google Scholar
• Hartner JC, Schmittwolf C, Kispert A, et al. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem. 2004;279(6):4894–4902.
   PubMed Web of Science ®Google Scholar
• Picardi E, Manzari C, Mastropasqua F, et al. Profiling RNA editing in human tissues: towards the inosinome Atlas. Sci Rep. 2015;5(1):14941.
   PubMedGoogle Scholar
• Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009;10(10):691–703.
   PubMed Web of Science ®Google Scholar
• Korenberg JR, Rykowski MC. Human genome organization: alu, lines, and the molecular structure of metaphase chromosome bands. Cell. 1988;53(3):391–400.
   PubMed Web of Science ®Google Scholar
• Daniel C, Lagergren J, Ohman M. RNA editing of non-coding RNA and its role in gene regulation. Biochimie. 2015;117:22–27.
   PubMed Web of Science ®Google Scholar
• Li JB, Levanon EY, Yoon J-K, et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science. 2009;324(5931):1210–1213.
   PubMed Web of Science ®Google Scholar
• Pullirsch D, Jantsch MF. Proteome diversification by adenosine to inosine RNA editing. RNA Biol. 2010;7(2):205–212.
   PubMed Web of Science ®Google Scholar
• Yeo J, Goodman RA, Schirle NT, et al. RNA editing changes the lesion specificity for the DNA repair enzyme NEIL1. Proc Natl Acad Sci U S A. 2010;107(48):20715–20719.
   PubMed Web of Science ®Google Scholar
• Galeano F, Rossetti C, Tomaselli S, et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene. 2013;32(8):998–1009.
   PubMed Web of Science ®Google Scholar
• Han SW, Kim H-P, Shin J-Y, et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J Exp Med. 2014;211(4):613–621.
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Li A, Kossenkov AV, et al. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis. Nat Commun. 2016;7(1):10715.
   PubMedGoogle Scholar
• Chen YB, Liao X-Y, Zhang J-B, et al. ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma. Int J Oncol. 2017;50(2):622–630.
   PubMed Web of Science ®Google Scholar
• Chan TH, Qamra A, Tan KT, et al. ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer. Gastroenterology. 2016;151(4):637–650 e10.
   PubMed Web of Science ®Google Scholar
• Kung CP, Maggi LB Jr., Weber JD. The role of RNA editing in cancer development and metabolic disorders. Front Endocrinol (Lausanne). 2018;9:762.
   PubMed Web of Science ®Google Scholar
• Zhang M, Fritsche J, Roszik J, et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018;9(1):3919.
   PubMed Web of Science ®Google Scholar
• Goncharov AO, Kliuchnikova AA, Nasaev SS, et al. RNA editing by ADAR adenosine deaminases: from molecular plasticity of neural proteins to the mechanisms of human cancer. Biochemistry (Mosc). 2019;84(8):896–904.
   PubMed Web of Science ®Google Scholar
• Tusup M, Kundig T, Pascolo S. Epitranscriptomics of cancer. World J Clin Oncol. 2018;9(3):42–55.
   PubMed Web of Science ®Google Scholar
• Mannion NM, Greenwood SM, Young R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014;9(4):1482–1494.
   PubMed Web of Science ®Google Scholar
• Shoshan E, Mobley AK, Braeuer RR, et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015;17(3):311–321.
   PubMed Web of Science ®Google Scholar
• Velazquez-Torres G, Shoshan E, Ivan C, et al. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun. 2018;9(1):461.
   PubMed Web of Science ®Google Scholar
• Nemlich Y, Greenberg E, Ortenberg R, et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013;123(6):2703–2718.
   PubMed Web of Science ®Google Scholar
• Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21(23):8984.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF -mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in Columbus: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33–44.
   PubMed Web of Science ®Google Scholar
• Garutti M, Targato G, Buriolla S, et al. CDK4/6 inhibitors in melanoma: a comprehensive review. Cells. 2021;10(6):1334.
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–251.
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Bartnik E, Fiedorowicz M, et al. Targeted therapy in melanoma and mechanisms of resistance. Int J Mol Sci. 2020;21(13):4576.
   PubMed Web of Science ®Google Scholar
• Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377–391.
   PubMed Web of Science ®Google Scholar
• Tusup M, Cheng PF, Picardi E, et al. Evaluation of the interplay between the ADAR editome and immunotherapy in melanoma. Noncoding RNA. 2021;7(1). DOI:10.3390/ncrna7010005.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MI, Widmer DS, Maudrich M, et al. A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Exp Dermatol. 2015;24(5):377–380.
   PubMed Web of Science ®Google Scholar
• Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. Apmis. 2007;115(10):1161–1176.
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103.
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF -mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–235.
   PubMed Web of Science ®Google Scholar
• Tsark EC, Adamson ED, Withers GE, et al. Expression and function of amphiregulin during murine preimplantation development. Mol Reprod Dev. 1997;47(3):271–283.
   PubMed Web of Science ®Google Scholar
• Busser B, Sancey L, Brambilla E, et al. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119–131.
   PubMed Web of Science ®Google Scholar
• Hutchinson KE, Johnson DB, Johnson AS, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6(26):22348–22360.
   PubMedGoogle Scholar
• Castillo J, Erroba E, Perugorria MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006;66(12):6129–6138.
   PubMed Web of Science ®Google Scholar
• Busser B, Sancey L, Josserand V, et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther. 2010;18(3):528–535.
   PubMed Web of Science ®Google Scholar
• Kamino H. Spitzoid melanoma. Clin Dermatol. 2009;27(6):545–555.
   PubMed Web of Science ®Google Scholar
• Darmawan CC, Jo G, Montenegro SE, et al. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81(3):805–812.
   PubMed Web of Science ®Google Scholar
• Forschner A, Forchhammer S, Bonzheim I. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications. J Dtsch Dermatol Ges. 2020;18(12):1387–1392.
   Web of Science ®Google Scholar
• Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst. 2019;111(10):1068–1077.
   PubMedGoogle Scholar
• Lezcano C, Shoushtari AN, Ariyan C, et al. Primary and metastatic melanoma with NTRK fusions. Am J Surg Pathol. 2018;42(8):1052–1058.
   PubMed Web of Science ®Google Scholar
• Yeh I, Botton T, Talevich E, et al. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun. 2015;6(1):7174.
   PubMedGoogle Scholar
• Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46.
   PubMed Web of Science ®Google Scholar
• Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5(1):3116.
   PubMedGoogle Scholar
• Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27(4):590–600.
   PubMed Web of Science ®Google Scholar
• Rossi M, Pellegrini C, Cardelli L, et al. Familial melanoma: diagnostic and management implications. Dermatol Pract Concept. 2019;9(1):10–16.
   PubMedGoogle Scholar
• Roth SH, Levanon EY, Eisenberg E. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity. Nat Methods. 2019;16(11):1131–1138.
   PubMed Web of Science ®Google Scholar
• Picardi E, D’Erchia AM, Lo Giudice C, et al. REDIportal: a comprehensive database of A-to-I RNA editing events in humans. Nucleic Acids Res. 2017;45(D1):D750–D757.
   PubMed Web of Science ®Google Scholar
• Silvestris DA, Picardi E, Cesarini V, et al. Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. Genome Biol. 2019;20(1):33.
   PubMedGoogle Scholar
• Ishizuka JJ, Manguso RT, Cheruiyot CK, et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019;565(7737):43–48.
   PubMed Web of Science ®Google Scholar
• Barak M, Levanon EY, Eisenberg E, et al. Evidence for large diversity in the human transcriptome created by Alu RNA editing. Nucleic Acids Res. 2009;37(20):6905–6915.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Akashi M, Nishida E. Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells. 1999;4(5):299–309.
   PubMed Web of Science ®Google Scholar
• Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 1996;44(5):323–330.
   PubMed Web of Science ®Google Scholar
• Dannenmann SR, Hermanns T, Bransi A, et al. Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunol Res. 2013;1(5):288–295.
   PubMed Web of Science ®Google Scholar
• Gotte K, Usener D, Riedel F, et al. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol. 2002;122(5):546–552.
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002;86(6):979–982.
   PubMed Web of Science ®Google Scholar
• Cha HJ, Kim J, Hong SM, et al. Overexpression of renal tumor antigen is associated with tumor invasion and poor prognosis of hepatocellular carcinoma. Ann Surg Oncol. 2012;19(Suppl S3):S404–11.
   PubMedGoogle Scholar
• Qian J, Chen Q, Yao D-M, et al. MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia. Int J Clin Exp Pathol. 2015;8(1):127–136.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Ikawa Y, Shibuya M, et al. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. J Biol Chem. 2001;276(24):21841–21848.
   PubMed Web of Science ®Google Scholar
• Sun J, Carr MJ, Khushalani NI. Principles of targeted therapy for melanoma. Surg Clin North Am. 2020;100(1):175–188.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–1270.
   PubMed Web of Science ®Google Scholar
• Kozar I, Margue, C, Rothengatter, S, et al. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019;1871(2):313–322.
   PubMed Web of Science ®Google Scholar
• Tian Y, Guo W. A review of the molecular pathways involved in resistance to BRAF inhibitors in patients with advanced-stage melanoma. Med Sci Monit. 2020;26:e920957.
   PubMed Web of Science ®Google Scholar
• Siggs OM, Beutler B. The BTB-ZF transcription factors. Cell Cycle. 2012;11(18):3358–3369.
   PubMed Web of Science ®Google Scholar
• Lee SU, Maeda T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol Rev. 2012;247(1):107–119.
   PubMedGoogle Scholar
• Phan RT, Saito M, Basso K et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6(10):1054–1060.
   PubMed Web of Science ®Google Scholar
• Suliman BA, Xu D, Williams BR. The promyelocytic leukemia zinc finger protein: two decades of molecular oncology. Front Oncol. 2012;2:74.
   PubMedGoogle Scholar
• Xiang T, Tang J, Li L, et al. Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis. Theranostics. 2019;9(26):8182–8195.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu X, Zhu J, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep. 2007;18(4):943–951.
   PubMed Web of Science ®Google Scholar
• Garipler G, Lu C, Morrissey A, et al. The BTB transcription factors ZBTB11 and ZFP131 maintain pluripotency by pausing POL II at pro-differentiation genes. Cell Rep. 2020;38(11):110524.
   Web of Science ®Google Scholar
• Haghighi F, Dahlmann J, Nakhaei-Rad S, et al. bFGF-mediated pluripotency maintenance in human induced pluripotent stem cells is associated with NRAS-MAPK signaling. Cell Commun Signal. 2018;16(1):96.
   PubMedGoogle Scholar
• Purcell DJ, Chauhan S, Jimenez-Stinson D, et al. Novel CARM1-interacting protein, DZIP3, is a transcriptional coactivator of estrogen receptor-alpha. Mol Endocrinol. 2015;29(12):1708–1719.
   PubMedGoogle Scholar
• Kolapalli SP, Sahu R, Chauhan NR, et al. RNA-Binding RING E3-Ligase DZIP3/hRUL138 stabilizes cyclin D1 to drive cell-cycle and cancer progression. Cancer Res. 2021;81(2):315–331.
   PubMed Web of Science ®Google Scholar
• Litchfield K, Reading JL, Puttick C, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596–614 e14.
   PubMed Web of Science ®Google Scholar
• Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177–183.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890.
   PubMed Web of Science ®Google Scholar
• Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
   PubMed Web of Science ®Google Scholar
• Patro R, Duggal G, Love MI, et al. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–419.
   PubMed Web of Science ®Google Scholar
• Law CW, Chen Y, Shi W, et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
   PubMed Web of Science ®Google Scholar
• Picardi E, Pesole G. REDItools: high-throughput RNA editing detection made easy. Bioinformatics. 2013;29(14):1813–1814.
   PubMed Web of Science ®Google Scholar
• Zaranek AW, Levanon EY, Zecharia T et al. A survey of genomic traces reveals a common sequencing error, RNA editing, and DNA editing. PLoS Genet. 2010;6(5):e1000954.
   PubMed Web of Science ®Google Scholar
• Lo Giudice C, Silvestris DA, Roth SH, et al. Quantifying RNA editing in deep transcriptome datasets. Front Genet. 2020;11:194.
   PubMed Web of Science ®Google Scholar